BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion

2025-12-19 | original

read original get Amicus Therapeutics → more articles

BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.

Explore topics: amicus amicus therapeutics billion billion cash biomarin